Ed M Behrens
Children Hospital of Philadelphia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ed M Behrens as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:31 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03113760 · Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP DeficiencyAB2 Bio Ltd. · completed · NLRC4-MAS, XIAP Deficiency · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- IL-33 Blockade as a Novel Therapeutic for T-cell Mediated Hypercytokinemia SyndromesR01AI121250 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2016 to 2020 · $586,684 awarded in 2020Same name and institution; not confirmed by an ID
- The Opposing Roles of IL-10 and IFN-gamma in Macrophage Activation SyndromeR01HL112836 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2013 to 2017 · $415,967 awarded in 2017Same name and institution; not confirmed by an ID
- Mechanisms and Therapeutic Use of CR3 Signaling in Modulating AutoimmunityK08AI079396 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2009 to 2013 · $133,920 awarded in 2013Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:31 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed